Q32 Bio’s bempikibart is starting to separate from JAK inhibitors in alopecia areata after additional Phase 2 results, with the company saying part B of the SIGNAL-AA trial showed reduced disease severity in severe patients. Q32 framed the mechanism as IL-7Rα blockade that re-regulates adaptive immune signaling driving hair-follicle attack. In parallel market coverage, Q32’s shares surged on the favorable Phase 2 development, reflecting investor focus on non-JAK approaches that may avoid JAK-class safety limitations. The company’s differentiation strategy also leans on potential durability of regrowth measured through SALT-based endpoints. The updates arrive as Q32 continues to position bempikibart as an alternative for patients who have not only severe alopecia but may also be exposed to prior biologic therapies, including JAK inhibitors.